logo
Plus   Neg
Share
Email

AstraZeneca Reports Detailed Results From Phase III DAPA-HF Trial - Quick Facts

AstraZeneca (AZN.L,AZN) announced that detailed results from the Phase III DAPA-HF trial showed that Farxiga on top of standard of care reduced both the incidence of cardiovascular death and the worsening of heart failure. The topline results announced in the previous month demonstrated that DAPA-HF met the primary endpoint.

Separately AstraZeneca (AZN.L, AZN) presented detailed results from the Phase III THEMIS trial, in which Brilinta plus aspirin reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone. The company said it will work with regulatory authorities to explore an update to the Brilinta label.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple is tracking iPhones that were stolen from its retail stores in recent days during the civil unrest, according to reports citing a warning message popping up on the stolen iPhones. Four current and former senior executives from two major broiler chicken producers, including Pilgrim's Pride CEO Jayson Penn, have been indicted for price fixing. Kezar Life Sciences, Inc. (KZR) - Shares of the clinical-stage biotechnology company soared nearly 80% after closing bell. The company's lead drug candidate is KZR-616, a selective inhibitor of immunoproteasome that plays a crucial role in the immune system. KZR-616 is under a phase Ib/II study in...
Follow RTT